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Managing orthopaedic pain in horses 
 
Introduction 
Orthopaedic pain is a broad term applied to pathology of the musculoskeletal system, potentially 
involving bones, joints, tendons, ligaments and muscles and consequently incorporating both soft 
and hard tissues. When thinking in terms of appropriate therapeutics, it may therefore be more 
useful to define it as deep somatic pain to distinguish it from superficial (cutaneous) somatic pain 
and visceral pain. 
Musculoskeletal pain may result from trauma (including planned surgical intervention), overuse, 
inflammation, infection, neoplasia, osteolysis, ischaemia or neuronal damage. Common equine 
orthopaedic conditions such as degenerative joint disease, navicular syndrome and laminitis often 
present several of these aspects in combination and can be challenging to manage. Difficulty can be 
compounded by occurrence of acute-on-chronic flare-ups (see Box 1 for some definitions associated 
with pain). 
The nature, severity and types of pain all must be taken into consideration when deciding how to 
provide effective analgesia. 
 
Pain recognition 
One of the biggest challenges in veterinary medicine is the recognition and quantification of pain. 
Assessment of pain in non-verbal species (and non-verbal humans) is difficult and subjective, 
typically relying on a combination of physiological variables, behaviour assessment and a degree of 
anthropomorphism. Several attempts have been made to devise pain scales for use in horses to 
identify the site and type of pain, but as yet none of these has been fully validated. This is further 
complicated by the fact that horses as a species tend not to be overtly demonstrative of pain unless 
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it is moderate to severe, show considerable variation in the way they respond and alter their 
behaviour in the presence of an observer. Different assessors may therefore attribute very different 
levels of pain to the same animal, leading to very different assessments of the requirement for 
analgesia. In the current context, lameness scores are crude but clinically useful and widely 
employed.  Manifestation of musculoskeletal pain may be obvious in the case of a single limb 
lameness, less so in mild multiple limb lameness, post surgically, or in cases of axial rather than 
appendicular pathology.  
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Strategic Analgesia 
A good analgesic plan will consist of systemically administered drugs, if possible in combination with 
local or regional analgesic techniques. Drugs chosen should ideally be those licensed for analgesia in 
the horse by the prescribed route, however licensed drugs administered by an unlicensed route, or 
unlicensed drugs may on occasion be indicated and appropriate. The key is in understanding the 
types of pain that may be present, the mode of action of the drugs that are available and how these 
drugs may be employed to maximise their effect on the case in question. In this way a multi-modal 
therapeutic plan can be formulated, incorporating the most appropriate drugs, designed to target as 
many aspects of the pain pathway as accurately as possible.  
Box 1. 
Types of Pain 
Acute pain - Acute pain is the normal physiological response to application of a noxious stimulus. It 
is designed to be protective, being linked to the withdrawal reflex, preventing further tissue 
damage and triggering behavioural changes intended to maximise healing. This type of pain is 
typically of short duration, persisting only as long as the original insult. This is the type of pain 
associated with the early stages of tissue injury or surgery and is relatively easy to treat. 
Chronic pain – this is pain that persists beyond the time frame expected for the relevant condition, 
a period of three to six months is often quoted. Thus may be due to acute injury or disease that is 
not resolving, ongoing degenerative conditions such as arthritis, or failure to manage acute pain 
adequately in the arly stages of treatment. Achieving satisfactory analgesia can be extremely 
difficult in chronic pain states as the nervous system undergoes maladaptive changes – a process 
called neuroplasticity. This can result in sensitisation of the nervous system, when normally 
innocuous sensory input becomes perceived as painful (termed allodynia) or an exaggerated 
response to normally painful stimuli (termed hyperalgesia). Sensitisation may occur in both 
peripheral and central components of the nervous system and involves increased reactivity of 
peripheral nociceptors and central pain neurons, recruitment of additional nociceptors to generate 
pain signals and upregulation of pain receptor expression, so reinforcing the pain transmission 
pathways. In cases where chronic pain develops, pain ceases to become simply an indicator of a 
disease process and becomes part of the disease process itself. The longer pain is left untreated or 
inadequately controlled the more difficult it becomes to obtain a satisfactory outcome. 
Neuropathic pain – this is pain caused by direct peripheral or central nerve injury resulting in 
hyperalgesia, allodynia and chronic, spontaneous ectopic generation of pain signals in the absence 
of any external stimuli.   
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Systemic administration of analgesic agents in the short term is typically by the intravenous (IV) or 
intramuscular (IM) route, with oral medication often being relied on for more protracted courses of 
treatment. Whilst a combination of these routes will probably prove adequate in the majority of 
cases, other methods of drug delivery may allow for more effective provision of analgesia in specific 
cases.  
The oral-transmucosal (OTM) absorption of some drugs can result in rapid uptake and high 
bioavailability as it avoids first pass metabolism which enterally absorbed drugs administered per os 
(PO) are subject to.  Although potentially very effective, drugs administered this way may be 
swallowed or spat out, resulting in imprecise dosing, restricting this method to either highly 
concentrated formulations or highly potent drugs, where a small total volume can be given.  
Although several drugs can be effectively administered this way, only the alpha 2 agonist detomidine 
has a formulation licenced specifically for this route.  
Transdermal drug delivery systems have been developed for a number of classes of drugs in the 
human market and include patches, creams and gels for external application designed to have either 
systemic or local effects. Transdermal drug absorption avoids first pass metabolism and gives the 
potential for prolonged drug administration with minimal patient handling. However drug uptake is 
highly dependent on sustained contact with the skin and that the area of application is healthy and 
has a good blood supply. Several human preparations have been evaluated in veterinary species and 
a specific veterinary formulation of fentanyl (licenced for use in dogs) is now available.  
Epidural drug administration (Fig 1) provides the opportunity for a more targeted effect and is 
becoming more commonly employed.  Use of local anaesthetics, alpha 2 agonists, opioids, ketamine 
and tramadol has been reported in the horse by this route. Depending on the characteristics of the 
drug, there will be varying systemic uptake, and onset and duration of effect may differ significantly 
from those familiar from conventional systemic administration, which can be advantageous. For 
prolonged analgesia, epidural catheters can be placed which facilitate provision of extended 
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targeted pain management (Fig 2). Commercial kits (Fig 3) for this procedure are available ( B Braun 
Medical Ltd, Yorkshire, UK; Smiths Medical, Kent, UK) and have been used successfully in several 
cases at the author’s hospital. These catheters require very careful management, with maintenance 
of patency and sterility being the main problems, however with proper management it is possible to 
maintain these in situ for up to 10 days in clinical cases. 
Diffusion (soaker) catheters offer the potential for prolonged, precise administration of local 
anaesthetic agents. Their potential has yet to be fully realised and they are discussed in more detail 
below with local anaesthetic drugs.  
With the high prevalence of developmental, degenerative and traumatic  disease affecting the joints 
of horses, as well as the frequency of diagnostic and therapeutic surgical procedures involving joints 
and other synovial structures, intra-synovial administration of analgesic agents is an attractive and 
effective method of achieving targeted pain relief. Administration of a number of drugs by this route 
has been described, including morphine, corticosteroids and local anaesthetic agents.  
 
Non-Steroidal Anti-inflammatory Drugs (NSAIDs) 
There are several non-steroidal anti-inflammatory drugs licenced for use in horses in the UK and 
these often form the first line and mainstay of analgesia provision. Action is by inhibition of cyclo-
oxygenase enzymes both peripherally and centrally, thereby interrupting the arachidonic acid 
cascade that results in production of prostacyclin, prostaglandins and thromboxanes. These 
substances are potent inflammatory mediators, which result in sensitisation and recruitment of 
peripheral nociceptors and transmission of central pain pathways. Many disease processes and 
certainly surgical interventions will induce an inflammatory response, so incorporating an anti-
inflammatory drug is eminently appropriate.  
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Many are available for administration by IV injection and as powders and/or pastes for oral 
administration, making them convenient for both acute and chronic pain management, although 
palatability may be problematic with some of the powdered preparations designed to be mixed with 
food. Choice largely comes down to familiarity, availability and cost. Anecdotally, some horses will 
respond better to one than another so it may be worth trying an alternative if response to one is 
unsatisfactory. Data sheets tend to advise leaving 24 hours between dosing if changing to an 
alternative to avoid inadvertent overdose. The potential for toxicity also need to be considered in 
the context of long term treatment, particularly as this may be continued by the owner of the horse 
for extended periods, outside the direct control of the veterinary surgeon. Doses should be carefully 
calculated and dosing regimes clearly stipulated. Toxicity may manifest as blood dyscrasias and 
gastrointestinal ulceration, with the glandular region of the stomach, proximal duodenum and right 
dorsal colon being particularly affected. Renal papillary necrosis has also been reported in horses 
receiving clinically relevant doses of phenylbutazone (Read 1983). This is particularly relevant as the 
aminoglycoside antimicrobial gentamicin, commonly used as a first line treatment in cases of 
synovial sepsis is also known to be nephrotoxic. 
 
Paracetamol (acetaminophen)  
Veterinary licensed oral preparations of paracetamol are available for dogs (in combination with 
codeine) and pigs in the UK, but not horses. This is not a typical NSAID and the exact mechanism of 
action is undetermined but thought to act centrally on serotonergic, opioid, nitric oxide and 
cannabinoid pathways as well as effects on prostaglandin production (Sharma and Mehta 2013). Its 
successful use as an adjunctive analgesic medication has been reported (20mg/kg PO twice daily) in 
a laminitic pony showing pain refractory to NSAIDs, lidocaine and morphine analgesia (West and 
others 2011).   
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Corticosteroids  
Corticosteroids act by inhibiting both cyclo-oxygenase and lipoxygenase pathways of the arachidonic 
acid cascade, exerting potent anti-inflammatory activity as well as a wide range of other effects.  
M st commonly utilised when discrete foci of inflammation can be precisely targeted using small 
volumes, such as vertebral or limb synovial or ligamentous structures.  Methylprednisolone and 
dexamethasone are licenced for systemic and intra-synovial use in horses. Data sheets invariably 
carry warnings about the risk of inducing or exacerbating laminitis and total dose and frequency of 
administration should be carefully considered. Triamcinolone although not licenced is also 
frequently used. 
 
Opioids 
This is a versatile group of drugs offering IV, IM, OTM, transdermal, epidural and intra synovial 
routes of administration. Action is primarily by central modulation of the pain pathways although 
opioid receptors are also present outside the central nervous system in tissues such as the myenteric 
plexus and synovial membranes, with expression being upregulated in inflammatory states. 
Butorphanol, pethidine and buprenorphine are licensed for use in horses in the UK and all 
demonstrate different receptor activity and affinity.  
Pethidine (meperidine) is a mu receptor agonist, making it potentially the most efficacious of the 
licenced options. Used at 1mg/kg IM it was shown to improve experimentally induced foot 
lameness, but only at 2-3hrs post administration (Foreman and Ruemmler 2013). Despite its 
theoretical promise, several factors limit its clinical utility. It is only licenced as a visceral analgesic, IV 
administration is contra-indicated due to potential for histamine release and seizure-like activity, it 
can cause pain on IM injection and large volumes need to be injected due to its low potency. It is 
also a Schedule 2 Controlled Drug, with the associated administrative requirements. Epidural 
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administration of pethidine (0.8mg/kg) has been reported, giving a fast onset (12 minutes) and 4 to 5 
hour duration of action (Skarda and Muir 2001). 
Buprenorphine (a Schedule 3 Controlled Drug) is a partial mu agonist, with some potentially 
attractive attributes and is licenced for post-operative analgesia at a dose of 10μg/kg IV. It is highly 
potent, requiring small volumes of administration and somatic analgesia of 6hrs duration (assessed 
experimentally using thermal threshold testing) is reported at this dose (Carregaro and others 2007).   
Buprenorphine also shows very good absorption by the OTM route, facilitating administration to 
needle shy horses.  A sublingual dose of 6μg/kg is reported to have produced effective sedation and 
analgesia lasting up to 12hrs in a case of trauma-associated musculoskeletal pain (Walker 2007). The 
author has used it with apparent good effect by this route. Data sheet recommendations state 
buprenorphine should only be administered after an intravenous sedative agent and cardiovascular 
stimulation and locomotor excitement lasting for over 12hours have been reported following the 
recommended dosing regimen (Carregaro and others 2006, 2007) and the author has seen horses 
compulsively box-walking following use in clinical cases.  
Butorphanol is a mu receptor antagonist and kappa receptor agonist. Whilst analgesia is reported as 
excellent or good in clinical colic cases (Stout and Priest 1986), it does not perform so well for 
somatic pain. In experimental horses Kalpravidh and others (1984a, 1984b) demonstrated only 
moderate analgesia lasting 15-30 minutes, assessed using thermal threshold testing. Increased heart 
rate and locomotor activity may also be seen, although in the author’s experience this is not as 
marked as that seen following buprenorphine administration. Epidural administration of 
butorphanol failed to produce detectable analgesia (Natalini and Robinson 2000), suggesting that 
horses do not possess kappa receptors in the spinal cord. It is then logical to assume that kappa 
agonists will only have a supraspinal effect. 
 
Unlicenced opioids.  
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In the author’s hospital, morphine (0.1-0.3mg/kg) is routinely given systemically (IM and IV) for 
perioperative analgesia and managing pain not controlled by NSAID administration. Morphine and 
methadone are also administered regularly by the epidural route for painful hindlimb orthopaedic 
conditions. Epidurally, morphine (0.1–0.2 mg/kg) (Sysel and others 1996, Goodrich and others 2002) 
shows a slow onset (up to 6 hours) and a duration of action of around 5 hours (Natalini and 
Robinson 2000), but can possibly last up to 12 - 18 hours. Epidural methadone (0.1mg/kg) has an 
onset of around 15 minutes and lasts about 5 hours (Olbrich and Mosing 2003). In the author’s 
hospital it is routine to combine methadone and morphine (0.1mg/kg of each) to obtain the 
theoretical advantage of providing rapid onset of analgesia with extended duration in the acute 
setting. Methadone also has activity at the N-methyl-D-aspartate (NMDA) receptor, therefore has an 
additional mechanism for contributing to analgesia. Where sustained provision of targeted analgesia 
is required, morphine can be administered at 0.1-0.2mg/kg twice daily via an indwelling epidural 
catheter. It is important to ensure strict aseptic technique and that preservative free solutions are 
used where possible. 
Intra-synovial administration of 0.05mg/kg morphine has also been demonstrated to provide 
analgesia for potentially 24 hours in experimentally induced radio-carpal joint synovitis (Lindegaard 
and others 2010a and 2010b).  
The availability of fentanyl patches offers the attractive prospect of providing extended opioid 
analgesia with minimal intervention. Maxwell and others (2003) showed rapid uptake by the 
transdermal route with all horses exceeding the 1ng/mL plasma level consistent with that reported 
to provide analgesia in other species, which was maintained for 32 hours. Orsini and others (2006) 
examined the pharmacokinetics of transdermal fentanyl using commercially available patches 
targeted to deliver 60μg/kg and found a large variation in onset of absorption (up to 5 hours), time 
to peak concentration (8.5-14.5 hours) and maximum plasma concentration achieved (0.67-
5.12ng/mL). One third of horses failed to achieve the 1ng/mL plasma concentration considered to be 
Page 9 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
analgesic. A large variation in onset, maximum concentration (0.1-28.7ng/mL) and time to maximum 
concentration (8-24 hours) has also been reported in neonatal foals treated with fentanyl patches 
designed to deliver 100μg/hr
 
(Eberspacher and others 2008).  The site of patch application is known 
to affect the rate and uptake of transdermally delivered fentanyl (Mills and Cross 2007). 
Combination therapy with NSAIDs has been reported in clinical cases refractory to NSAID treatment 
alone (Thomasy and others 2004). Again, a large variation in maximum concentration and time to 
achieve this were reported, but some, although weak, evidence of analgesic effect was claimed. A 
solution of fentanyl (50mg/mL) is licenced for transdermal use in dogs where it is claimed to provide 
analgesia for a minimum of 4 days post-application, but this has not been evaluated in horses at the 
time of writing. 
 
Alpha 2 adrenergic agonists  
Frequently used as sedative agents, alpha 2 agonist compounds also provide analgesia by a 
mechanism similar to, and synergistic with, that of the opioids (Hellyer and others 2003). Duration 
and quality of analgesia is controversial (England and Clarke 1996), but appears to be better for 
visceral, rather than somatic pain. Some authors have reported no detectable influence on somatic 
analgesia (Elfenbein and others 2009), whilst others have found that the effect depends not only on 
the drug used, but also on the type of stimulus applied (Moens and others 2003, Rohrbach and 
others 2009). Given systemically, analgesia is best considered to be of short duration, peaking later 
than sedative effects and not lasting as long, making them of most use during surgical procedures.  
All alpha 2 agonists have profound effects on the cardiovascular system which should also be taken 
into account, as should the difficulty of assessing adequate analgesia in a sedated animal.  
Epidurally, xylazine (0.17mg/kg up to 0.25mg/kg) is safe and effective (LeBlanc and Carron 1990; 
Skarda and Muir 1996; LeBlanc and others 1998). Detomidine (30µg/kg) in combination with 
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0.2mg/kg morphine produces analgesia (Skarda and Muir 1996, Sysel and others 1996, Goodrich and 
others 2002) and reduces post-operative lameness after hindlimb surgery (Sysel and others 1996, 
Goodrich and others 2002). High lipid solubility facilitates systemic absorption from the epidural 
space, especially of detomidine (Skarda and Muir 1996), causing sedation following epidural 
administration. Loss of tail and perineal muscle tone may become evident due to local anaesthetic-
like properties (particularly with xylazine). Onset is rapid (approximately 12 minutes) and duration of 
effect is 2.5-3.5 hours (LeBlanc and others 1998, Skarda and Muir 1996). 
 
Local Anaesthetic Agents 
Local anaesthetics have the potential to completely abolish pain by interrupting neuronal signal 
transmission, rather than just obtunding it. They affect both sensory and motor neurons, 
consequently their use will not be appropriate for all sites of pain or surgery, but where applicable 
they offer considerable benefit. They can be administered topically, perineurally, epidurally, intra-
synovially, systemically and directly infiltrated into tissues. Mepivacaine, lidocaine and procaine are 
all licenced for use in horses in the UK. Of these, only mepivacaine is supplied without adrenaline or 
preservative and is licensed for infiltration, perineural, intra-articular and epidural administration, 
making it an extremely versatile preparation. Lidocaine without adrenaline is also available from 
pharmaceutical suppliers as a 2% solution for injection and as a 0.2% solution in 5% glucose for IV 
infusion, but not licenced for use in horses.  
Lidocaine administration has been described by continuous IV infusion (loading dose of up to 
2mg/kg followed by infusion at 50µg/kg/minute). Its use in this manner is most often associated 
with gastrointestinal tract surgery, however somatic analgesia as assessed by thermal threshold 
testing has been demonstrated experimentally (Robertson and others 2005).  
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Epidurally, care needs to be taken with the total volume injected to avoid cranial spread which may 
impair motor function to the hindlimbs (Goodrich and others 2002, Olbrich and Mosing 2003). 
Preservative free preparations of bupivacaine 0.5%, lidocaine 2% and mepivacaine 2% solutions (5-
10mL) have been used by the author.  
Transdermal patches containing 5% lidocaine are used to treat a range of chronic neuropathic and 
musculoskeletal pain in humans, with systemic uptake having been proven. Application of two 
700mg patches to the limbs of horses for 12 hours failed to demonstrate systemic uptake in a study 
by Bidwell and others (2007). Doubling the number of patches for 24 hours gave variable systemic 
uptake (Andreoni and Giorgi 2009). If the skin was subjected to an alcohol scrub prior to patch 
placement there was a tendency for a more rapid and pronounced, but less sustained uptake. 
Antinociceptive effects assessed by pricking the skin under the patch at removal showed no 
difference in sensation between horses which had had a patch applied and control animals. This 
application therefore appears to be of little benefit. 
Diffusion catheters (Fig 4) are another method of providing targeted pain relief. These are available 
commercially (Mila International Inc, Kentucky, USA) or can be improvised from narrow gauge plastic 
tubing or intravenous cannulae. The use of these for prolonged perineural administration of 
lidocaine, mepivacaine and bupivacaine to the palmar metacarpal nerves has been investigated 
experimentally in horses (Driessen and others 2008). Although regional anaesthesia was achieved, 
significant oedema developed, necessitating discontinuation of the infusions, limiting their clinical 
potential. Alternatively, catheter implantation during wound closure, allowing local anaesthetic to 
be instilled directly at the surgical site for post-operative pain management has been described in 
small animals (Abelson and others 2009) with no associated risk of wound complications and has 
been successfully used in horses at the author’s hospital to provide analgesia for 48 hours following 
surgical resection of thoracolumbar spinous processes (Fig 5).  
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Prolonged intra-synovial administration of local anaesthetic agents in human patients has been 
associated with chondrolysis, with bupivacaine appearing to exhibit the greatest degree of 
chondrotoxicity. This effect appears to be dose and time dependent, being particularly pronounced 
with formulations containing adrenaline. Consequently a number of local anaesthetic agents have 
been tested in animal models and chondrocyte cultures, with mixed results; in vitro results not 
always supporting in vivo ones (Webb and Ghosh 2009; Dragoo and others 2010). An in vitro study of 
bupivacaine, lidocaine and mepivacaine on equine chondrocyte cultures showed mepivacaine to be 
the least chondrotoxic, with cell viability on exposure to this agent approaching that of the saline 
control (Park and others 2011). Single intra-synovial injection of local anaesthetic solution is 
performed regularly at the author’s hospital to provide targeted pain relief following arthroscopic 
surgery, with no apparent problem.  
 
Ketamine 
Used at sub-anaesthetic doses, this NMDA receptor antagonist has potent analgesic properties and 
may counteract central sensitization, so making it potentially useful in the management of chronic as 
well as acute pain. Infusions of 0.4 and 0.8mg/kg/hour have been shown to be tolerated well in 
conscious horses, with excitement seen at 1.6mg/kg/hour, although no somatic analgesia was 
demonstrated (Fielding and others 2006). Peterbauer and others (2008) however, did demonstrate 
analgesic properties in conscious horses after 0.6mg/kg IV bolus followed by 20µg/kg/minute 
infusion. Analgesia is mainly somatic rather than visceral and is mediated by a number of 
mechanisms in addition to NMDA receptor activity. In addition to infusion administration, IM bolus 
dosing at 0.2-0.5mg/kg has been practiced by the author to manage acute episodes of pain, or 
acute-on-chronic episodes in cases of laminitis or following surgical intervention. Epidural 
administration (0.5, 1.0 and 2.0mg/kg) has been shown to provide analgesia lasting 30 to 75 minutes 
(De Segura and others 1998). 
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Tramadol 
Tramadol is a synthetic analogue of codeine which has been used in the management of acute and 
chronic moderate to severe pain in humans. It is a centrally acting analgesic that has agonist activity 
at mu opioid receptors and also inhibits the reuptake of noradrenaline and serotonin. Although not 
licenced in the horse, the pharmacokinetics and pharmacodynamics of intravenously, 
intramuscularly and orally administered tramadol have been investigated in this species (Shilo and 
others 2007, Cox and others 2010, Dhanjal and others 2009, Knych and others 2013a 2013b, Giorgi 
and others 2007, Stewart and others 2011). Minimum plasma tramadol levels which provide 
analgesia in people vary greatly between 100 and 600ng/mL, with much of the analgesic effect of 
tramadol being attributed to the M1 metabolite (O-desmethyltramadol) which has 200 times the 
affinity for the mu opioid receptor than the parent drug. In people there is genetically 
predetermined variation in the ability to produce this metabolite, making some individuals poorly 
responsive to the drug. It is unknown whether this is also true in horses, although a large individual 
variation in plasma concentrations of MI (and several other metabolites) has been demonstrated (De 
Leo and others 2009, Knych and others 2013a, 2013b, Giorgi and others 2007). Oral bioavailability 
following a 5mg/kg dose has been reported as approximately 65% in fasted horses, increasing to 
approximately 85% in fed horses (Giorgi and others 2007), whilst Shilo and others (2007) reported 
only 3% following 2mg/kg administered to fasted horses. Knych and others (2013a) used doses of 3, 
6 and 9mg/kg PO which showed a very wide variation in plasma levels, with only the 9mg/kg dose 
consistently achieving plasma concentrations within the human analgesic range. No adverse events 
were reported apart from mild signs of colic and increased pacing behaviour in 1 horse at the higher 
dose. Intramuscular administration of 2mg/kg resulted in rapid and complete absorption with 
attainment of useful plasma concentrations and no adverse effects (Shilo and others 2007). Cox and 
others (2010) and Shilo and others (2007) reported side effects including ataxia, muscle twitching 
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and sweating for 15 minutes after 2mg/kg IV and Giorgi and others (2007) reported confusion, 
agitation, tremor and tachycardia after 5mg/kg IV but not PO. Dhanjal and others (2009) reported 
side effects following 2mg/kg IV and were unable to demonstrate an antinociceptive effect using a 
noxious thermal stimulus. Guedes and others (2012) administered 5mg/kg PO twice daily to horses 
with chronic laminitic pain and showed only weak evidence of analgesia, whilst ketamine showed a 
much greater effect. Epidural administration of 1mg/kg tramadol produced analgesia after 30 
minutes with effects lasting for 4 hours (Natalini and Robinson 2000). 
 
Gabapentin 
Originally used as an adjuvant anticonvulsant, gabapentin was subsequently shown to be effective in 
treating a range of chronic pain syndromes in people. It is a structural analogue of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) but neither parent drug nor metabolites show affinity 
for, or activity at GABAA or GABAB receptors. The major mechanism of action is currently thought to 
be via voltage dependent calcium channels, thereby reducing neurotransmitter release (Kong and 
Irwin 2007). Pharmacokinetics of a single dose of 5mg/kg PO (Dirikolu and others 2008) and 20mg/kg 
PO and IV (Terry and others 2010) have been evaluated in horses. No adverse events were noted 
after either dose or route of administration although sedation was evident for 1 hour after the IV 
dose. Rapid but poor absorption (compared with humans, rats, dogs and monkeys) followed PO 
administration with a bioavailability of only 16% following the higher dose. Gabapentin is not 
licensed for veterinary species but there are case reports of its use in horses. Davis and others (2007) 
describe its use in a heavily pregnant mare with suspected neuropathic pain  at 2.5mg/kg PO every 8 
hours, increasing dosing interval over 6 days, with apparent beneficial effect and no detriment to the 
foetus. It is also reported as a component of a multimodal approach to provision of analgesia in the 
management of severe laminitis associated hoof pain, at doses between 3.3mg/kg every 8 hours and 
2mg/kg every 12 hours PO (Dutton and others 2009). 
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Bisphosphonates 
Bisphosphonates have been shown to reduce pain in human patients with osteoarthritis and cancer 
pain and improve joint mobility. These drugs inhibit osteoclast proton secretion, reducing the acidity 
of the microenvironment associated with bone resorption, so reducing activation of acid sensitive 
ion channels in sensory neurons. A direct anti-inflammatory effect is also demonstrated by inhibiting 
osteoblast secretion of vascular endothelial growth factor, reducing cytokine release from activated 
macrophages (Silvina and Barbara 2014). Tiludronic acid is licenced for treatment of inflammatory 
and degenerative joint disease in horses at a dose of 1mg/kg by intravenous infusion over 30 
minutes. Improvement of lameness in horses suffering from bone spavin (Gough and others 2010) 
and navicular disease (Denoix and others 2003) has been demonstrated in tiludronate treated 
horses.  
Isoxsuprine hydrochloride is licenced for the treatment of navicular disease in horses. Its action 
causes vasodilation, lowers blood viscosity and inhibits platelet aggregation, thereby potentially 
improving circulation in the affected area. Some, but inconsistent evidence of clinical efficacy has 
been shown (Rose and others 1983; Turner and Tucker 1989). 
Conclusion  
The World Health Organisation ‘pain ladder’ (Fig 6) describes a graded approach to administration of 
analgesic agents, combined with adjunctive therapies and provides a useful framework to follow for 
pain management. Originally designed to provide guidance managing cancer pain in people, is now 
much more widely applied. The number of drugs available for use in horses is limited, however by 
understanding the action of what is available and adopting a multi-modal approach, additive or 
synergistic activities can be exploited to maximise effect whilst minimising the risk of side effects. 
Adjunctive therapies can equally be vital in achieving a successful outcome (Fig 7). These range from 
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simple bandaging, hot and cold compresses or using ice, physiotherapy, acupuncture, corrective or 
remedial farriery up to surgical interventions such as hoof wall resection, and salvage procedures 
such as neurectomy (sometimes in conjunction with fasciotomy) and arthrodesis.  Novel attributes 
of drugs used for other indications can also be exploited for good effect, for example the use of 
tricyclic antidepressants for chronic pain management in people and small animals.  However 
evidence of safety and efficacy in the horse in this regard is often lacking. 
Quiz 
1. In addition to being a general anaesthetic agent, ketamine provides profound analgesia via 
its action at NMDA receptors. Which of the following drugs also has NMDA receptor activity? 
a) Gabapentin  
b) Methadone  
c) Paracetamol 
d) Tramadol  
 
2. Which of the following statements is true of alpha 2 agonists? 
a) They provide reliable somatic analgesia 
b) The analgesia they provide lasts as long as the sedative effects 
c) They are all licensed for administration by the oral transmucosal route 
d) It is possible to achieve sedation by administering them into the epidural space 
 
3. The following classes of drugs can effectively be administered epidurally, except for which 
one? 
a) Alpha 2 agonists 
b) Non-steroidal anti-inflammatories 
c) Opioids 
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d) Local anaesthetics 
 
4. Which of the following statements is true regarding intra-synovial administration of 
analgesic agents? 
a) Local anaesthetics should never be used due to their chondrotoxic effects 
b) There are no drugs licenced for use by this route in the horse 
c) Total dose of corticosteroids should be restricted due to the potential for adverse 
systemic side effects 
d) There are no opioid receptors present in synovial tissue therefore these drugs will not be 
effective by this route 
 
Answers: 1 b), 2 d), 3 b), 4 c). 
Contributorship 
The author is the sole contributor to this article and accepts responsibility for its content. 
References 
ABELSON, A.L., McCOBB, E. C., SHAW, S., ARMITAGE-CHAN, E., WETMORE, L. A., KARAS, A., Z. & 
BLAZE, C. (2009) Use of wound soaker catheters for the administration of local anaesthetic for post-
operative analgesia: 56 cases. Veterinary Anaesthesia and Analgesia 36, 597-602 
 
ANDREONI, V.A. & GIORGI, M. (2009) Evaluation of plasma detectable concentrations of two 
lidocaine transdermal formulations and their analgesic effect in the horse. Journal of Equine 
Veterinary Science 29, 681-686 
 
BIDWELL, L.A., WILSON, D.V. & CARON, J.P. (2007) Lack of systemic absorption of lidocaine from 5% 
patches placed on horses. Veterinary Anaesthesia and Analgesia 34, 443-446 
Page 18 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
CARREGARO, A.B., TEIXEIRA NETO, F.J., BEIER, S.L. & LUNA, S.P. (2006) Cardiopulmonary effects of 
buprenorphine in horses. American Journal of Veterinary Research 67, 1675-1680 
 
CARREGARO, A.B., LUNA, S.P.L., MATAQUEIRO, M.I. & QUEIROZ-NETO, A. (2007) Effects of 
buprenorphine on nociception and spontaneous locomotor activity in horses. American Journal of 
Veterinary Research 68, 246-250 
 
COX, S., VILLARINO, N. & DOHERTY, T. (2010) Determination of oral tramadol pharmacokinetics in 
horses. Research in Veterinary Science 89, 236-241 
 
DAVIS, J.L., POSNER, L.P. & ELCE, Y. (2007) Gabapentin for the treatment of neuropathic pain in a 
pregnant horse. Journal of the American Veterinary Medical Association 231, 755-758 
 
DE LEO, M., GIORGI, M., SACCOMANNI, G., MANERA, C. & BRACA, A. (2009) Evaluation of tramadol 
and its main metabolites in horse plasma by high performance liquid chromatography/fluorescence 
and liquid chromatography/electrospray ionization tandem mass spectrometry techniques. Rapid 
Communications in Mass Spectrometry 23, 228-236 
 
DHANJAL, J.K., WILSON, D.V., ROBINSON, E., TOBIN, T.T. & DIROKULU, L. (2009) Intravenous 
tramadol: effects, nociceptive properties and pharmacokinetics in horses. Veterinary Anaesthesia 
and Analgesia 36, 581-590 
 
Page 19 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
DENOIX, J-M., THIBAUD, D. & RICCIO, B. (2003) Tiludronate as a new therapeutic agent in the 
treatment of navicular disease: a double blind placebo controlled clinical trial. Equine Veterinary 
Journal 35, 407-413 
 
DIRIKOLU, L., DAFALLA, A., ELY, K.J., CONNERLY, A.L., JONES, C.N., ELKHOLY, H., LEHNER, A.F., 
THOMPSON, K. & TOBIN, T. (2008) Pharmacokinetics of gabapentin in horses. Journal of Veterinary 
Pharmacology and Therapeutics 3, 175-177 
 
DRAGOO, J.L., KOROTKOVA, T., KIM, H.J. & JAGADISH, A. (2010) Chondrotoxicity of low pH, 
epinephrine, and preservatives found in local anesthetics containing epinephrine. American Journal 
of Sports Medicine 38, 1154-1159 
 
DRIESSEN, B., SCANDELLA, M. & ZARUCCO, L. (2008) Development of a technique for continuous 
perineural blockade of the palmar nerves in the distal equine thoracic limb. Veterinary Anaesthesia 
and Analgesia 35, 432-44 
 
DUTTON, D.W., LASHNITS, K.J., WEGNER, K. (2009) Managing severe hoof pain in a horse using 
multimodal analgesia and a modified composite pain score. Equine Veterinary Education 21, 37-43 
 
EBERSPACHER, E., STANLEY, S.D., REZENDE, M. & STEFFEY, E.P. (2008) Pharmacokinetics and 
tolerance of transdermal fentanyl administration in foals. Veterinary Anaesthesia and Analgesia 35, 
249-255 
 
ELFENBEIN, J.R., SANCHEZ, L.C., ROBERTSON, S., COLE, C.A. & SAMS, R. (2009) Effect of detomidine 
on visceral and somatic nociception and duodenal motility in conscious adult horses. Veterinary 
Anaesthesia and Analgesia 36, 162-172 
Page 20 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
ENGLAND, G.C.W. & CLARKE, K.W. (1996) Alpha 2 adrenoceptor agonists in the horse – a review. 
British Veterinary Journal 152, 641-657 
 
FIELDING, C.L., BRUMBAUGH, G.W., MATTHEWS, N.S., PECK, K.E. & ROUSSEL, A.J. (2006) 
Pharmacokinetics and clinical effects of a subanaesthetic continuous rate infusion of ketamine in 
awake horses. American Journal of Veterinary Research 67, 1484-1490 
 
FOREMAN, J.H. & RUEMMLER, R. (2013) Efficacy of intramuscular meperidine hydrochloride versus 
placebo in experimental foot lameness in horses. Equine Veterinary Journal 45, 48-53 
 
GIORGI, M., SOLDANI, G., MANERA, C., FERRARINI, P., SGORBINI, M. & SACCOMANNI, G. (2007) 
Pharmacokinetics of tramadol and its metabolites M1, M2 and M5 in horses following intravenous, 
immediate release (fasted/fed) and sustained release single dose administration. Journal of Equine 
Veterinary Science 27, 481-487 
 
DE SEGURA, I. A.G., DE ROSSI, R., SANTOS, M., SAN-ROMAN, J.L. & TENDILLO, F.J. (1998) Epidural 
injection of ketamine for perineal analgesia in the horse. Veterinary Surgery 27, 384-391 
 
GOODRICH, L.R., NIXON, A.J., FUBINI, S.L., DUCHARME, N.G., FORTIER, L.A., WARNICK, L.D. & 
LUDDERS, J.W. (2002) Epidural morphine and detomidine decreases post-operative hindlimb 
lameness in horses after bilateral stifle arthroscopy. Veterinary Surgery 31, 232-239 
 
GOUGH, M.R., THIBAUD, D. & SMITH, R.K.W. (2010) Tiludronate infusion in the treatment of bone 
spavin: a double blind placebo controlled trial. Equine Veterinary Journal 42, 381-387 
 
Page 21 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
GUEDES, A.G.P., MATTHEWS, N.S. & HOOD, D.M. (2012) Effect of ketamine hydrochloride on the 
analgesic effects of tramadol hydrochloride in horses with signs of chronic laminitis associated pain. 
American Journal of Veterinary Research 73, 610-619 
 
HELLYER, P.W., BAI, L., SUPON, J., QUAIL, C., WAGNER, A.E., MAMA, K.R. & MAGNUSSON, K.R. (2003) 
Comparison of opioid and alpha 2 adrenergic receptor binding in horse and dog brain using 
radioligand autoradiography. Veterinary Anaesthesia and Analgesia 30, 172-182 
 
KALPRAVIDH, M., LUMB, W.V., WRIGHT, M. & HEATH, R.B. (1984a) Analgesic effects of butorphanol 
in horses: dose-response studies. American Journal of Veterinary Research 45, 211-216 
 
KALPRAVIDH, M., LUMB, W.V., WRIGHT, M. & HEATH, R.B. (1984b) Effects of butorphanol, flunixin, 
levorphanol, morphine and xylazine in ponies. American Journal of Veterinary Research 45, 217-223 
 
KNYCH, H.K., CORADO, C.R., McKEMIE, D.S., SCHOLTZ, E. & SAMS, R. (2013a) Pharmacokinetics and 
pharmacodynamics of tramadol in horses following oral administration. Journal of Veterinary 
Pharmacology and Therapeutics 36, 389-398 
 
KNYCH, H.K., CORADO, C.R., McKEMIE, D.S. & STEFFEY, E.P. (2013b) Pharmacokinetics and selected 
pharmacodynamics effects of tramadol following intravenous administration to the horse. Equine 
Veterinary Journal 45, 490-496 
 
KONG, V.K.F. 7 IRWIN, M.G. (2007) Gabapentin: a multimodal perioperative drug? British Journal of 
Anaesthesia 99, 775-786 
 
Page 22 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
LeBLANC, P.H. & CARRON, J.P. (1990) Clinical use of epidural xylazine in the horse. Equine Veterinary 
Journal 22, 180-181 
 
LeBLANC, P.H., CARON, J.P., PATTERSON, J.S., BROWN, M. & MATTA, M.A. (1998) Epidural injection 
of xylazine for perineal analgesia in horses. Journal of the American Veterinary Medical Association 
193, 1405-1408 
 
LINDEGAARD, C., THOMSEM, M.H., LARSEN, S. & ANDERSEN, P.H. (2010a) Analgesic efficacy of intra-
articular morphine in experimentally induced radiocarpal synovitis in horses. Veterinary Anaesthesia 
and Analgesia 37, 171-185 
 
LINDEGAARD, C., FROST, A. B., THOMSEN, M. H., LARSEN, C., HANSEN, S. H. & ANDERSEN P. H. 
(2010b) Pharmacokinetics of intra-articular morphine in horses with lipopolysaccharide-induced 
synovitis Veterinary Anaesthesia and Analgesia  37, 186-195 
 
MAXWELL, L.K., THOMASY, S.M., SLOVIS, N. & KOLLIAS-BAKER, C. (2003) Pharmacokinetics of 
fentanyl following intravenous and transdermal administration in horses. Equine Veterinary Journal 
35, 484-490 
 
MILLS, P.C. & CROSS, S.E. (2007) Regional differences in transdermal penetration of fentanyl through 
equine skin. Research in Veterinary Science 82, 252-256 
 
MOENS, Y., LANZ, F., DOHERR, M.G. & SCHATZMANN, U. (2003) A comparison of the antinociceptive 
effects of xylazine, detomidine and romifidine on experimental pain in horses. Veterinary 
Anaesthesia and Analgesia 30, 183-190 
 
Page 23 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
NATALINI, C.C. & ROBINSON, E.P. (2000) Evaluation of the analgesic effects of epidurally 
administered morphine, alfentanil, butorphanol, tramadol and U50488H in horses. American Journal 
of Veterinary Research 61, 1579-86 
 
OLBRICH, V.H. & MOSING M. (2003) A comparison of the analgesic effects of caudal epidural 
methadone and lidocaine in the horse. Veterinary Anaesthesia and Analgesia 30, 156-164 
 
ORSINI, J.A., MOATE, P.J., KUERSTEN, K., SOMA, L.R. & BOSTON, R.C. (2006) Pharmacokinetics of 
fentanyl delivered transdermally in healthy adult horses – variability among horses and its clinical 
implications. Journal of Veterinary Pharmacology and Therapeutics 29, 539-546 
 
PARK, J., SUTRADHAR, B. C., HONG, G., CHOI, S. H. & KIM, G. (2011) Comparison of the cytotoxic 
effects of bupivacaine, lidocaine, and mepivacaine in equine articular chondrocytes. Veterinary 
Anaesthesia and Analgesia 38, 127–133  
 
PETERBAUER, C., LARENZA, P.M., KNOBLOCH, M., THEURILLAT, R., THORMANN, W., MEVISSEN, M. & 
SPADAVECCHIA, C. (2008) Effects of low dose infusion of racemic and S-ketamine on the nociceptive 
withdrawal reflex in standing ponies. Veterinary Anaesthesia and Analgesia 35, 414-423 
 
READ, W.K. (1983) Renal medullary crest necrosis associated with phenylbutazone therapy in horses. 
Veterinary Pathology 20, 662-669 
 
ROBERTSON, S.A., SANCHEZ, L.C., MERRITT, A.M. & DOHERTY, T.J. (2005) Effects of systemic 
lidocaine on visceral and somatic nociception in conscious horses. Equine Veterinary Journal 37, 122-
127 
 
Page 24 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
ROHRBACH, H., KORPIVAARA, T., SCHATZMANN, U. & SPADAVECCHIA, C. (2009) Comparison of the 
effects of the alpha-2 agonists detomidine, romifidine and xylazine on nociceptive withdrawal reflex 
and temporal summation in horses. Veterinary Anaesthesia and Analgesia 36, 384-395 
 
ROSE, R. J., ALLEN, J. R., HODGSON, D. R. & KOHNKE, J. R. (1983) Studies on isoxsuprine 
hydrochloride for the treatment of navicular disease. Equine Veterinary Journal 15, 238-243 
 
SHARMA, C.V. & MEHTA, V. (2013) Paracetamol: mechanisms and updates. Continuing Education in 
Anaesthesia, Critical Care and Pain 14, 153-158 
 
SHILO, Y., BRITZI, M., EYTAN, B., LIFSCHITZ, T., SOBACK, S. & STEINMAN, A. (2007) Pharmacokinetics 
of tramadol in horses after intravenous, intramuscular and oral administration. Journal of Veterinary 
Pharmacology and Therapeutics 31, 60-65 
 
SILVINA, S. & BARBARA, A.C. (2014) Bisphosphonates: pharmacology and clinical approach to their 
use in equine osteoarticular diseases. Journal of Equine Veterinary Science 34, 727-737 
 
SKARDA, R.T. & MUIR, W.W. (1996) Comparison of antinociceptive, cardiovascular and respiratory 
effects, head ptosis and position of pelvic limbs in mares after caudal epidural administration of 
xylazine and detomidine hydrochloride solutions. American Journal of Veterinary Research 57, 1338-
1345 
 
SKARDA, R.T. & MUIR, W.W. (2001) Analgesic, hemodynamic and respiratory effects induced by 
caudal epidural administration of meperidine hydrochloride in mares. American Journal of 
Veterinary Research 62, 1001-1007 
Page 25 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
STEWART, A.J., BOOTHE, D.M., CRUZ-ESPINDOLA, C., MITCHUM, E.J. & SPRINGFIELD, J. (2011) 
Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in 
adult horses. American Journal of Veterinary Research 72, 967-974 
 
STOUT, R.C. & PRIEST, G.T. (1986) Clinical experience using butorphanol tartrate for relief of 
abdominal pain in the horse. Equine Colic Research, Proceedings of the second Symposium at the 
University of Georgia, Lawrenceville, NJ: Veterinary Learning Systems Vol 2. 
 
SYSEL, A.M., PLEASANT, R.S., JACOBSON, J.D., MOLL, H.D., MODRANSKY, P.D., WARNICK, L.D., 
SPONENBERG, D.P. & EYRE, P. (1996) Efficacy of an epidural combination of morphine and 
detomidine in alleviating experimentally induced hindlimb lameness in horses. Veterinary Surgery 
25, 511-518 
 
TERRY, R.L., McDONNELL, S.M., VAN EPS, A.W., SOMA, L.R., LIU, Y., UBOH, C.E., MOATE, P.J. & 
DRIESSEN, B. (2010) Pharmacokinetic profile and behavioural ffects of gabapentin in the horse. 
Journal of Veterinary Pharmacology and Therapeutics 33, 485-494 
 
THOMASY, S.M., SLOVIS, N., MAXWELL, L.K. & KOLLIAS-BAKER, C. (2004) Transdermal fentanyl 
combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. Journal of Veterinary 
Internal Medicine 18, 550-554 
 
TURNER, A. S. & TUCKER, C. M. (1989) The evaluation of isoxsuprine hydrochloride for the treatment 
of navicular disease: a double blind study. Equine Veterinary Journal 21, 338-341 
 
Page 26 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
WALKER, A.F. (2007) Sublingual administration of buprenorphine for long term analgesia in the 
horse. Veterinary Record 160, 808-809 
 
WEBB, S. T. & GHOSH, S. (2009) Intra-articular bupivacaine: potentially chondrotoxic? British Journal 
of Anaesthesia 102, 439-441  
 
WEST, E., BARDELL, D., MORGAN, R. & SENIOR, J.M. (2011) Use of acetaminophen (paracetamol) as a 
short term adjunctive analgesic in a laminitic pony. Veterinary Anaesthesia and Analgesia 38, 521-
522 
 
Further reading 
 
Veterinary Clinics of North America: Equine Practice. Volume 26, Issue 3, pages 467-680 (December 
2010). Pain in Horses: Physiology, Pathophysiology and Therapeutic Implications. Ed W. W. Muir. 
Elsevier. 
 
 
 
 
 
 
 
 
 
 
 
Page 27 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Figure 1. 
Epidural injection (here shown being performed at the sacro-coccygeal/first inter-coccygeal space) is 
a useful technique for achieving more targeted drug delivery. It is important to observe good 
hygiene and where possible to use preservative free drugs. 
 
Figure 2. 
Epidural catheter placed at the sacro-coccygeal/first inter-coccygeal space. Note the bacterial filter 
and sterile dressing to maintain cleanliness. With appropriate care, these can be maintained for 
several days for extended pain management without the requirement for repeated needle puncture. 
 
Figure 3. 
Commercially available epidural catheter kits. Several makes are available and contain all the 
necessary components.   
 
Figure 4. 
Commercially available wound diffusion catheters. These are available with different diffusion 
lengths so can be chosen to suit the extent of the surgical field. Home-made ones can be 
constructed from long intravenous cannulae or dog urinary catheters. 
 
Figure 5. 
Commercial wound diffusion catheter in-situ following spinous process resection. The catheter is 
placed during wound closure and exited through a stab incision distant from the surgical site. Note 
the bacterial filter to preserve sterility of injected local anaesthetic agent. 
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Figure 6. 
World Health Organisation ‘Pain Ladder’. Originally designed for guidance in managing cancer pain in 
people, it describes a logical, progressive approach to provision of analgesic agents when managing 
many types of clinical pain.  
 
Figure 7. 
Severe case of laminitis. These cases can be extremely challenging to manage, often presenting with 
complex pain that is refractory to conventional analgesic protocols. Adjunctive approaches are as 
important as pharmacological therapy, with hoof wall resection and provision of adequate 
mechanical support illustrated here. 
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Managing orthopaedic pain in horses 
 
Introduction 
Orthopaedic pain is a broad term applied to pathology of the musculoskeletal system, potentially 
involving bones, joints, tendons, ligaments and muscles and consequently incorporating both soft 
and hard tissues. When thinking in terms of appropriate therapeutics, it may therefore be more 
useful to define it as deep somatic pain to distinguish it from superficial (cutaneous) somatic pain 
and visceral pain. 
Musculoskeletal pain may result from trauma (including planned surgical intervention), overuse, 
inflammation, infection, neoplasia, osteolysis, ischaemia or neuronal damage. Common equine 
orthopaedic conditions such as degenerative joint disease, navicular syndrome and laminitis often 
present several of these aspects in combination and can be challenging to manage. Difficulty can be 
compounded by occurrence of acute-on-chronic flare-ups (see Box 1 for some definitions associated 
with pain). 
The nature, severity and types of pain all must be taken into consideration when deciding how to 
provide effective analgesia. 
 
Pain recognition 
One of the biggest challenges in veterinary medicine is the recognition and quantification of pain. 
Assessment of pain in non-verbal species (and non-verbal humans) is difficult and subjective, 
typically relying on a combination of physiological variables, behaviour assessment and a degree of 
anthropomorphism. Several attempts have been made to devise pain scales for use in horses to 
identify the site and type of pain, but as yet none of these has been fully validated. This is further 
complicated by the fact that horses as a species tend not to be overtly demonstrative of pain unless 
Formatted
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it is moderate to severe, show considerable variation in the way they respond and alter their 
behaviour in the presence of an observer. Different assessors may therefore attribute very different 
levels of pain to the same animal, leading to very different assessments of the requirement for 
analgesia. In the current context, lameness scores are crude but clinically useful and widely 
employed.  Manifestation of musculoskeletal pain may be obvious in the case of a single limb 
lameness, less so in mild multiple limb lameness, post surgically, or in cases of axial rather than 
appendicular pathology.  
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Strategic Analgesia 
A good analgesic plan will consist of systemically administered drugs, if possible in combination with 
local or regional analgesic techniques. Drugs chosen should ideally be those licensed for analgesia in 
the horse by the prescribed route, however licensed drugs administered by an unlicensed route, or 
unlicensed drugs may on occasion be indicated and appropriate. The key is in understanding the 
types of pain that may be present, the mode of action of the drugs that are available and how these 
drugs may be employed to maximise their effect on the case in question. In this way a multi-modal 
therapeutic plan can be formulated, incorporating the most appropriate drugs, designed to target as 
many aspects of the pain pathway as accurately as possible.  
Box 1. 
Types of Pain 
Acute pain - Acute pain is the normal physiological response to application of a noxious stimulus. It 
is designed to be protective, being linked to the withdrawal reflex, preventing further tissue 
damage and triggering behavioural changes intended to maximise healing. This type of pain is 
typically of short duration, persisting only as long as the original insult. This is the type of pain 
associated with the early stages of tissue injury or surgery and is relatively easy to treat. 
Chronic pain – this is pain that persists beyond the time frame expected for the relevant condition, 
a period of three to six months is often quoted. Thus may be due to acute injury or disease that is 
not resolving, ongoing degenerative conditions such as arthritis, or failure to manage acute pain 
adequately in the early stages of treatment. Achieving satisfactory analgesia can be extremely 
difficult in chronic pain states as the nervous system undergoes maladaptive changes – a process 
called neuroplasticity. This can result in sensitisation of the nervous system, when normally 
innocuous sensory input becomes perceived as painful (termed allodynia) or an exaggerated 
response to normally painful stimuli (termed hyperalgesia). Sensitisation may occur in both 
peripheral and central components of the nervous system and involves increased reactivity of 
peripheral nociceptors and central pain neurones, recruitment of additional nociceptors to 
generate pain signals and upregulation of pain receptor expression, so reinforcing the pain 
transmission pathways. In cases where chronic pain develops, pain ceases to become simply an 
indicator of a disease process and becomes part of the disease process itself. The longer pain is left 
untreated or inadequately controlled the more difficult it becomes to obtain a satisfactory 
outcome. 
Neuropathic pain – this is pain caused by direct peripheral or central nerve injury resulting in 
hyperalgesia, allodynia and chronic, spontaneous ectopic generation of pain signals in the absence 
of any external stimuli.   
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Systemic administration of analgesic agents in the short term is typically by the intravenous (IV) or 
intramuscular (IM) route, with oral medication often being relied on for more protracted courses of 
treatment. Whilst a combination of these routes will probably prove adequate in the majority of 
cases, other methods of drug delivery may allow for more effective provision of analgesia in specific 
cases.  
The oral-transmucosal (OTM) absorption of some drugs can result in rapid uptake and high 
bioavailability as it avoids first pass metabolism which enterally absorbed drugs administered per os 
(PO) are subject to.  Although potentially very effective, drugs administered this way may be 
swallowed or spat out, resulting in imprecise dosing, restricting this method to either highly 
concentrated formulations or highly potent drugs, where a small total volume can be given.  
Although several drugs can be effectively administered this way, only the alpha 2 agonist detomidine 
has a formulation licenced specifically for this route.  
Transdermal drug delivery systems have been developed for a number of classes of drugs in the 
human market and include patches, creams and gels for external application designed to have either 
systemic or local effects. Transdermal drug absorption avoids first pass metabolism and gives the 
potential for prolonged drug administration with minimal patient handling. However drug uptake is 
highly dependent on sustained contact with the skin and that the area of application is healthy and 
has a good blood supply. Several human preparations have been evaluated in veterinary species and 
a specific veterinary formulation of fentanyl (licenced for use in dogs) is now available.  
Epidural drug administration (Fig 1) provides the opportunity for a more targeted effect and is 
becoming more commonly employed.  Use of local anaesthetics, alpha 2 agonists, opioids, ketamine 
and tramadol has been reported in the horse by this route. Depending on the characteristics of the 
drug, there will be varying systemic uptake, and onset and duration of effect may differ significantly 
from those familiar from conventional systemic administration, which can be advantageous. For 
prolonged analgesia, epidural catheters can be placed which facilitate provision of extended 
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targeted pain management (Fig 2). Commercial kits (Fig 3) for this procedure are available (Fig 3 B 
Braun Medical Ltd, Yorkshire, UK; Smiths Medical, Kent, UK) and have been used successfully in 
several cases at the author’s hospital. These catheters require very careful management, with 
maintenance of patency and sterility being the main problems, however with proper management it 
is possible to maintain these in situ for up to 10 days in clinical cases. 
Diffusion (soaker) catheters offer the potential for prolonged, precise administration of local 
anaesthetic agents. Their potential has yet to be fully realised and they are discussed in more detail 
below with local anaesthetic drugs.  
With the high prevalence of developmental, degenerative and traumatic  disease affecting the joints 
of horses, as well as the frequency of diagnostic and therapeutic surgical procedures involving joints 
and other synovial structures, intra-synovial administration of analgesic agents is an attractive and 
effective method of achieving targeted pain relief. Administration of a number of drugs by this route 
has been described, including morphine, corticosteroids and local anaesthetic agents.  
 
Non-Steroidal Anti-inflammatory Drugs (NSAIDs) 
The first line and mainstay of analgesia provision, tThere are several non-steroidal anti-inflammatory 
drugs licenced for use in horses in the UK and these often form the first line and mainstay of 
analgesia provision. Action is by inhibition of cyclo-oxygenase enzymes both peripherally and 
centrally, thereby interrupting the arachidonic acid cascade that results in production of 
prostacyclin, prostaglandins and thromboxanes. These substances are potent inflammatory 
mediators, which result in sensitisation and recruitment of peripheral nociceptors and transmission 
of central pain pathways. Many disease processes and certainly surgical interventions will induce an 
inflammatory response, so incorporating an anti-inflammatory drug is eminently appropriate.  
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Many are available for administration by IV injection and as powders and/or pastes for oral 
administration, making them convenient for both acute and chronic pain management, although 
palatability may be problematic with some of the powdered preparations designed to be mixed with 
food. Choice largely comes down to familiarity, availability and cost. Anecdotally, some horses will 
respond better to one than another so it may be worth trying an alternative if response to one is 
unsatisfactory. Data sheets tend to advise leaving 24 hours between dosing if changing to an 
alternative to avoid inadvertent overdose. The potential for toxicity also need to be considered in 
the context of long term treatment, particularly as this may be continued by the owner of the horse 
for extended periods, outside the direct control of the veterinary surgeon. Doses should be carefully 
calculated and dosing regimes clearly stipulated. Toxicity may manifest as blood dyscrasias and 
gastrointestinal ulceration, with the glandular region of the stomach, proximal duodenum and right 
dorsal colon being particularly affected. Renal papillary necrosis has also been reported in horses 
receiving clinically relevant doses of phenylbutazone (Read 1983). This is particularly relevant as the 
aminoglycoside antimicrobial gentamicin, commonly used as a first line treatment in cases of 
synovial sepsis is also known to be nephrotoxic. 
 
Paracetamol (acetaminophen)  
Veterinary licensed oral preparations of paracetamol are available for dogs (in combination with 
codeine) and pigs in the UK, but not horses. This is not a typical NSAID and the exact mechanism of 
action is undetermined but thought to act centrally on serotonergic, opioid, nitric oxide and 
cannabinoid pathways as well as effects on prostaglandin production (Sharma and Mehta 2013). Its 
successful use as an adjunctive analgesic medication has been reported (20mg/kg PO twice daily) in 
a laminitic pony showing pain refractory to NSAIDs, lidocaine and morphine analgesia (West and 
others 2011).   
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Corticosteroids  
Corticosteroids act byBy inhibiting both cyclo-oxygenase and lipoxygenase pathways of the 
arachidonic acid cascade, these drugs exerting potent anti-inflammatory activity as well as a wide 
range of other effects.  Most commonly utilised when discrete foci of inflammation can be precisely 
targeted using small volumes, such as vertebral or limb synovial or ligamentous structures.  
Methylprednisolone and dexamethasone are licenced for systemic and intra-synovial use in horses. 
Data sheets invariably carry warnings about the risk of inducing or exacerbating laminitis and total 
dose and frequency of administration should be carefully considered. Triamcinolone although not 
licenced is also frequently used. 
 
Opioids 
This is a versatile group of drugs offering IV, IM, OTM, transdermal, epidural and intra synovial 
routes of administration. Action is primarily by central modulation of the pain pathways although 
opioid receptors are also present outside the central nervous systemCNS in tissues such as the 
myenteric plexus and synovial membranes, with expression being upregulated in inflammatory 
states. 
Butorphanol, pethidine and buprenorphine are licensed for use in horses in the UK and all 
demonstrate different receptor activity and affinity.  
Pethidine (meperidine) is a mu receptor agonist, making it potentially the most efficacious of the 
licenced options. Used at 1mg/kg IM it was shown to improve experimentally induced foot 
lameness, but only at 2-3hrs post administration (Foreman and Ruemmler 2013). Despite its 
theoretical promise, several factors limit its clinical utility. It is only licenced as a visceral analgesic, IV 
administration is contra-indicated due to potential for histamine release and seizure-like activity, it 
can cause pain on IM injection and large volumes need to be injected due to its low potency. It is 
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also a Schedule 2 Controlled Drug, with the associated administrative requirements. Epidural 
administration of pethidine (0.8mg/kg) has been reported, giving a fast onset (12 minutes) and 4 to 5 
hour duration of action (Skarda and Muir 2001). 
Buprenorphine (a Schedule 3 Controlled Drug) is a partial mu agonist, with some potentially 
attractive attributes and is licenced for post-operative analgesia at a dose of 10μg/kg IV. It is highly 
potent, requiring small volumes of administration and somatic analgesia of 6hrs duration (assessed 
experimentally using thermal threshold testing) is reported at this dose (Carregaro and others 2007).   
Buprenorphine also shows very good absorption by the OTM route, facilitating administration to 
needle shy horses.  A sublingual dose of 6μg/kg is reported to have produced effective sedation and 
analgesia lasting up to 12hrs in a case of trauma-associated musculoskeletal pain (Walker 2007). The 
author has used it with apparent good effect by this route. Data sheet recommendations state 
buprenorphine should only be administered after an intravenous sedative agent and cardiovascular 
stimulation and locomotor excitement lasting for over 12hours have been reported following the 
recommended dosing regimen (Carregaro and others 2006, 2007) and the author has seen horses 
compulsively box-walking following use in clinical cases.  
Butorphanol is a mu receptor antagonist and kappa receptor agonist. Whilst analgesia is reported as 
excellent or good in clinical colic cases (Stout and Priest 1986), it does not perform so well for 
somatic pain. In experimental horses Kalpravidh and others (1984a, 1984b) demonstrated only 
moderate analgesia lasting 15-30 minutes, assessed using thermal threshold testing. Increased heart 
rate and locomotor activity may also be seen, although in the author’s experience this is not as 
marked as that seen following buprenorphine administration. Epidural administration of 
butorphanol failed to produce detectable analgesia (Natalini and Robinson 2000), suggesting that 
horses do not possess kappa receptors in the spinal cord. It is then logical to assume that kappa 
agonists will only have a supraspinal effect. 
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Unlicenced opioids.  
In the author’s hospital, morphine (0.1-0.3mg/kg) is routinely given systemically (IM and IV) for 
perioperative analgesia and managing pain not controlled by NSAID administration. Morphine and 
methadone are also administered regularly by the epidural route for painful hindlimb orthopaedic 
conditions. Epidurally, morphine (0.1–0.2 mg/kg) (Sysel and others 1996, Goodrich and others 2002) 
shows a slow onset (up to 6 hours) and a duration of action of around 5 hours (Natalini and 
Robinson 2000), but can possibly last up to 12 - 18 hours. Epidural methadone (0.1mg/kg) has an 
onset of around 15 minutes and lasts about 5 hours (Olbrich and Mosing 2003). In the author’s 
hospital it is routine to combine methadone and morphine (0.1mg/kg of each) to obtain the 
theoretical advantage of providing rapid onset of analgesia with extended duration in the acute 
setting. Methadone also has activity at the N-methyl-D-aspartate (NMDA) receptor, therefore has an 
additional mechanism for contributing to analgesia. Where sustained provision of targeted analgesia 
is required, morphine can be administered at 0.1-0.2mg/kg twice daily via an indwelling epidural 
catheter. It is important to ensure strict aseptic technique and that preservative free solutions are 
used where possible. 
Intra-synovial administration of 0.05mg/kg morphine has also been demonstrated to provide 
analgesia for potentially 24 hours in experimentally induced radio-carpal joint synovitis (Lindegaard 
and others 2010a and 2010b).  
The availability of fentanyl patches offers the attractive prospect of providing extended opioid 
analgesia with minimal intervention. Maxwell and others (2003) showed rapid uptake by the 
transdermal route with all horses exceeding the 1ng/mL plasma level consistent with that reported 
to provide analgesia in other species, which was maintained for 32 hours. Orsini and others (2006) 
examined the pharmacokinetics of transdermal fentanyl using commercially available patches 
targeted to deliver 60μg/kg and found a large variation in onset of absorption (up to 5 hours), time 
to peak concentration (8.5-14.5 hours) and maximum plasma concentration achieved (0.67-
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5.12ng/mL). One third of horses failed to achieve the 1ng/mL plasma concentration considered to be 
analgesic. A large variation in onset, maximum concentration (0.1-28.7ng/mL) and time to maximum 
concentration (8-24 hours) has also been reported in neonatal foals treated with fentanyl patches 
designed to deliver 100μg/hr
 
(Eberspacher and others 2008).  The site of patch application is known 
to affect the rate and uptake of transdermally delivered fentanyl (Mills and Cross 2007). 
Combination therapy with NSAIDs has been reported in clinical cases refractory to NSAID treatment 
alone (Thomasy and others 2004). Again, a large variation in maximum concentration and time to 
achieve this were reported, but some, although weak, evidence of analgesic effect was claimed. A 
solution of fentanyl (50mg/mL) is licenced for transdermal use in dogs where it is claimed to provide 
analgesia for a minimum of 4 days post-application, but this has not been evaluated in horses at the 
time of writing. 
 
Alpha 2 adrenergic agonists  
Frequently used as sedative agents, these alpha 2 agonist compounds also provide analgesia by a 
mechanism similar to, and synergistic with, that of the opioids (Hellyer and others 2003). Duration 
and quality of analgesia is controversial (England and Clarke 1996), but appears to be better for 
visceral, rather than somatic pain. Some authors have reported no detectable influence on somatic 
analgesia (Elfenbein and others 2009), whilst others have found that the effect depends not only on 
the drug used, but also on the type of stimulus applied (Moens and others 2003, Rohrbach and 
others 2009). Given systemically, analgesia is best considered to be of short duration, peaking later 
than sedative effects and not lasting as long, making them of most use during surgical procedures.  
All alpha 2 agonists have profound effects on the cardiovascular system which should also be taken 
into account, as should the difficulty of assessing adequate analgesia in a sedated animal.  
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Epidurally, xylazine (0.17mg/kg up to 0.25mg/kg) is safe and effective (LeBlanc and Carron 1990; 
Skarda and Muir 1996; LeBlanc and others 1998). Detomidine (30µg/kg) in combination with 
0.2mg/kg morphine produces analgesia (Skarda and Muir 1996, Sysel and others 1996, Goodrich and 
others 2002) and reduces post-operative lameness after hindlimb surgery (Sysel and others 1996, 
Goodrich and others 2002). High lipid solubility facilitates systemic absorption from the epidural 
space, especially of detomi ine (Skarda and Muir 1996), causing sedation following epidural 
administration. Loss of tail and p rineal muscle tone may become evident due to local anaesthetic-
like properties (particularly with xylazine). Onset is rapid (approximately 12 minutes) and duration of 
effect is 2.5-3.5 hours (LeBlanc and others 1998, Skarda and Muir 1996). 
 
Local Anaesthetic Agents 
Local anaesthetics have the potential to completely abolish pain by interrupting neuronal signal 
transmission, rather than just obtunding it. They affect both sensory and motor neurons, 
consequently their use will not be appropriate for all sites of pain or surgery, but where applicable 
they offer considerable benefit. They can be administered topically, perineurally, epidurally, intra-
synovially, systemically and directly infiltrated into tissues. Mepivacaine, lidocaine and procaine are 
all licenced for use in horses in the UK. Of these, only mepivacaine is supplied without adrenaline or 
preservative and is licensed for infiltration, perineural, intra-articular and epidural administration, 
making it an extremely versatile preparation. Lidocaine without adrenaline is also available from 
pharmaceutical suppliers as a 2% solution for injection and as a 0.2% solution in 5% glucose for IV 
infusion, but not licenced for use in horses.  
Lidocaine administration has been described by continuous IV infusion (loading dose of up to 
2mg/kg followed by infusion at 50µg/kg/minute). Its use in this manner is most often associated 
with gastrointestinal tract surgery, however somatic analgesia as assessed by thermal threshold 
testing has been demonstrated experimentally (Robertson and others 2005).  
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Epidurally, care needs to be taken with the total volume injected to avoid cranial spread which may 
impair motor function to the hindlimbs (Goodrich and others 2002, Olbrich and Mosing 2003). 
Preservative free preparations of bupivacaine 0.5%, lidocaine 2% and mepivacaine 2% solutions (5-
10mL) have been used by the author.  
Transdermal patches containing 5% lidocaine are used to treat a range of chronic neuropathic and 
musculoskeletal pain in humans, with systemic uptake having been proven. Application of two 
700mg patches to the limbs of horses for 12 hours failed to demonstrate systemic uptake in a study 
by Bidwell and others (2007). Doubling the number of patches for 24 hours gave variable systemic 
uptake (Andreoni and Giorgi 2009). If the skin was subjected to an alcohol scrub prior to patch 
placement there was a tendency for a more rapid and pronounced, but less sustained uptake. 
Antinociceptive effects assessed by pricking the skin under the patch at removal showed no 
difference in sensation between horses which had had a patch applied and control animals. This 
application therefore appears to be of little benefit. 
Diffusion catheters (Fig 4) are another method of providing targeted pain relief. These are available 
commercially  (Fig 4Mila International Inc, Kentucky, USA) or can be improvised from narrow gauge 
plastic tubing or intravenous cannulae. The use of these for prolonged perineural administration of 
lidocaine, mepivacaine and bupivacaine to the palmar metacarpal nerves has been investigated 
experimentally in horses (Driessen and others 2008). Although regional anaesthesia was achieved, 
significant oedema developed, necessitating discontinuation of the infusions, limiting their clinical 
potential. Alternatively, catheter implantation during wound closure, allowing local anaesthetic to 
be instilled directly at the surgical site for post-operative pain management has been described in 
small animals (Abelson and others 2009) with no associated risk of wound complications and has 
been successfully used in horses at the author’s hospital to provide analgesia for 48 hours following 
surgical resection of thoracolumbar dorsal spinous processes (Fig 5).  
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Prolonged intra-synovial administration of local anaesthetic agents in human patients has been 
associated with chondrolysis, with bupivacaine appearing to exhibit the greatest degree of 
chondrotoxicity. This effect appears to be dose and time dependent, being particularly pronounced 
with formulations containing adrenaline. Consequently a number of local anaesthetic agents have 
been tested in animal models and chondrocyte cultures, with mixed results; in vitro results not 
always supporting in vivo ones (Webb and Ghosh 2009; Dragoo and others 2010). An in vitro study of 
bupivacaine, lidocaine and mepivacaine on equine chondrocyte cultures showed mepivacaine to be 
the least chondrotoxic, with cell viability on exposure to this agent approaching that of the saline 
control (Park and others 2011). Single intra-synovial injection of local anaesthetic solution is 
performed regularly at the author’s hospital to provide targeted pain relief following arthroscopic 
surgery, with no apparent problem.  
 
Ketamine 
Used at sub-anaesthetic doses, this NMDA receptor antagonist has potent analgesic properties and 
may counteract central sensitization, so making it potentially useful in the management of chronic as 
well as acute pain. Infusions of 0.4 and 0.8mg/kg/hour have been shown to be tolerated well in 
conscious horses, with excitement seen at 1.6mg/kg/hour, although no somatic analgesia was 
demonstrated (Fielding and others 2006). Peterbauer and others (2008) however, did demonstrate 
analgesic properties in conscious horses after 0.6mg/kg IV bolus followed by 20µg/kg/minute 
infusion. Analgesia is mainly somatic rather than visceral and is mediated by a number of 
mechanisms in addition to NMDA receptor activity. In addition to infusion administration, IM bolus 
dosing at 0.2-0.5mg/kg has been practiced by the author to manage acute episodes of pain, or 
acute-on-chronic episodes in cases of laminitis or following surgical intervention. Epidural 
administration (0.5, 1.0 and 2.0mg/kg) has been shown to provide analgesia lasting 30 to 75 minutes 
(De Segura and others 1998). 
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Tramadol 
Tramadol is a synthetic analogue of codeine which has been used in the management of acute and 
chronic moderate to severe pain in humans. It is a centrally acting analgesic that has agonist activity 
at mu opioid receptors and also inhibits the reuptake of noradrenaline and serotonin. Although Nnot 
licenced in the horse, but the pharmacokinetics and pharmacodynamics of intravenously, 
intramuscularly and orally administered tramadol in horses have been investigated in this species 
(Shilo and others 2007, Cox and others 2010, Dhanjal and others 2009, Knych and others 2013a 
2013b, Giorgi and others 2007, Stewart and others 2011). Tramadol is a synthetic analogue of 
codeine which has been used in the management of acute and chronic moderate to severe pain in 
humans. It is a centrally acting analgesic that has agonist activity at mu opioid receptors and also 
inhibits the reuptake of noradrenaline and serotonin. Minimum plasma tramadol levels which 
provide analgesia in people vary greatly between 100 and 600ng/mL, with much of the analgesic 
effect of tramadol being attributed to the M1 metabolite (O-desmethyltramadol) which has 200 
times the affinity for the mu opioid receptor than the parent drug. In people there is genetically 
predetermined variation in the ability to produce this metabolite, making some individuals poorly 
responsive to the drug. It is unknown whether this is also true in horses, although a large individual 
variation in plasma concentrations of MI (and several other metabolites) has been demonstrated (De 
Leo and others 2009, Knych and others 2013a, 2013b, Giorgi and others 2007). Oral bioavailability 
following a 5mg/kg dose has been reported as approximately 65% in fasted horses, increasing to 
approximately 85% in fed horses (Giorgi and others 2007), whilst Shilo and others (2007) reported 
only 3% following 2mg/kg administered to fasted horses. Knych and others (2013a) used doses of 3, 
6 and 9mg/kg PO which showed a very wide variation in plasma levels, with only the 9mg/kg dose 
consistently achieving plasma concentrations within the human analgesic range. No adverse events 
were reported apart from mild signs of colic and increased pacing behaviour in 1 horse at the higher 
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dose. Intramuscular administration of 2mg/kg resulted in rapid and complete absorption with 
attainment of useful plasma concentrations and no adverse effects (Shilo and others 2007). Cox and 
others (2010) and Shilo and others (2007) reported side effects including ataxia, muscle twitching 
and sweating for 15 minutes after 2mg/kg IV and Giorgi and others (2007) reported confusion, 
agitation, tremor and tachycardia after 5mg/kg IV but not PO. Dhanjal and others (2009) reported 
side effects following 2mg/kg IV and were unable to demonstrate an antinociceptive effect using a 
noxious thermal stimulus. Guedes and others (2012) administered 5mg/kg PO twice daily to horses 
with chronic laminitic pain and showed only weak evidence of analgesia, whilst ketamine showed a 
much greater effect. Epidural administration of 1mg/kg tramadol produced analgesia after 30 
minutes with effects lasting for 4 hours (Natalini and Robinson 2000). 
 
Gabapentin 
Originally used as an adjuvant anticonvulsant, it gabapentin was subsequently shown to be effective 
in treating a range of chronic pain syndromes in people. It is a structural analogue of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) but neither parent drug nor metabolites show affinity 
for, or activity at GABAA or GABAB receptors. The major mechanism of action is currently thought to 
be via voltage dependent calcium channels, thereby reducing neurotransmitter release (Kong and 
Irwin 2007). Pharmacokinetics of a single dose of 5mg/kg PO (Dirikolu and others 2008) and 20mg/kg 
PO and IV (Terry and others 2010) have been evaluated in horses. No adverse events were noted 
after either dose or route of administration although sedation was evident for 1 hour after the IV 
dose. Rapid but poor absorption (compared with humans, rats, dogs and monkeys) followed PO 
administration with a bioavailability of only 16% following the higher dose. Not Gabapentin is not 
licensed for veterinary species but there is aare case reports of its use in horses. Davis and others 
(2007) describe its use in a heavily pregnant mare with suspected neuropathic pain (Davis and others 
2007) at 2.5mg/kg PO every 8 hours, increasing dosing interval over 6 days, with apparent beneficial 
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effect and no detriment to the foetus. It is also reported as a component of a multimodal approach 
to provision of analgesia in the management of severe laminitis associated hoof pain, at doses 
between 3.3mg/kg every 8 hours and 2mg/kg every 12 hours PO (Dutton and others 2009). 
 
Bisphosphonates 
Bisphosphonates have been shown to reduce pain in human patients with osteoarthritis and cancer 
pain and improve joint mobility. These drugs inhibit osteoclast proton secretion, reducing the acidity 
of the microenvironment associated with bone resorption, so reducing activation of acid sensitive 
ion channels in sensory neurons. A direct anti-inflammatory effect is also demonstrated by inhibiting 
osteoblast secretion of vascular endothelial growth factor, reducing cytokine release from activated 
macrophages (Silvina and Barbara 2014). Tiludronic acid is licenced for treatment of inflammatory 
and degenerative joint disease in horses at a dose of 1mg/kg by intravenous infusion over 30 
minutes. Improvement of lameness in horses suffering from bone spavin (Gough and others 2010) 
and navicular disease (Denoix and others 2003) has been demonstrated in tiludronate treated 
horses.  
Isoxsuprine hydrochloride is licenced for the treatment of navicular disease in horses. Its action 
causes vasodilation, lowers blood viscosity and inhibits platelet aggregation, thereby potentially 
improving circulation in the affected area. Some, but inconsistent evidence of clinical efficacy has 
been shown (Rose and others 1983; Turner and Tucker 1989). 
Conclusion  
The World Health Organisation ‘pain ladder’ (Fig 6) describes a graded approach to administration of 
analgesic agents, combined with adjunctive therapies and provides a useful framework to follow for 
pain management. Originally designed to provide guidance managing cancer pain in people, is now 
much more widely applied. The number of drugs available for use in horses is limited, however by 
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understanding the action of what is available and adopting a multi-modal approach, additive or 
synergistic activities can be exploited to maximise effect whilst minimising the risk of side effects. 
Adjunctive therapies can equally be vital in achieving a successful outcome (Fig 7). These range from 
simple bandaging, hot and cold compresses or using ice, physiotherapy, acupuncture, corrective or 
remedial farriery up to surgical interventions such as hoof wall resection, and salvage procedures 
such as neurectomy (sometimes in conjunction with fasciotomy) and arthrodesis.  Novel attributes 
of drugs used for other indications can also be exploited for good effect, for example the use of 
tricyclic antidepressants for chronic pain management in people and small animals.  However 
evidence of safety and efficacy in the horse in this regard is often lacking. 
Quiz 
1. In addition to being a general anaesthetic agent, ketamine provides profound analgesia via 
its action at NMDA receptors. Which of the following drugs also has NMDA receptor activity? 
a) Gabapentin  
b) Methadone  
c) Paracetamol 
d) Tramadol  
 
2. Which of the following statements is true of alpha 2 agonists? 
a) They provide reliable somatic analgesia 
b) The analgesia they provide lasts as long as the sedative effects 
c) They are all licensed for administration by the oral transmucosal route 
d) It is possible to achieve sedation by administering them into the epidural space 
 
3. The following classes of drugs can effectively be administered epidurally, except for which 
one? 
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a) Alpha 2 agonists 
b) Non-steroidal anti-inflammatories 
c) Opioids 
d) Local anaesthetics 
 
4. Which of the following statements is true regarding intra-synovial administration of 
analgesic agents? 
a) Local anaesthetics should never be used due to their chondrotoxic effects 
b) There are no drugs licenced for use by this route in the horse 
c) Total dose of corticosteroids should be restricted due to the potential for adverse 
systemic side effects 
d) There are no opioid receptors present in synovial tissue therefore these drugs will not be 
effective by this route 
 
Answers: 1 b), 2 d), 3 b), 4 c). 
Contributorship 
The author is the sole contributor to this article and accepts responsibility for its content. 
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Figure 1. 
Epidural injection (here shown being performed at the sacro-coccygeal/first inter-coccygeal space) is 
a useful technique for achieving more targeted drug delivery. It is important to observe good 
hygiene and where possible to use preservative free drugs. 
 
Figure 2. 
Epidural catheter placed at the sacro-coccygeal/first inter-coccygeal space. Note the bacterial filter 
and sterile dressing to maintain cleanliness. With appropriate care, these can be maintained for 
several days for extended pain management without the requirement for repeated needle puncture. 
 
Figure 3. 
Commercially available epidural catheter kits. Several makes are available and contain all the 
necessary components.   
 
Figure 4. 
Commercially available wound diffusion catheters. These are available with different diffusion 
lengths so can be chosen to suit the extent of the surgical field. Home-made ones can be 
constructed from long intravenous cannulae or dog urinary catheters. 
 
Figure 5. 
Commercial wound diffusion catheter in-situ following dorsal spinous process resection. The 
catheter is placed during wound closure and exited through a stab incision distant from the surgical 
site. Note the bacterial filter to preserve sterility of injected local anaesthetic agent. 
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Figure 6. 
World Health Organisation ‘Pain Ladder’. Originally designed for guidance in managing cancer pain in 
people, it describes a logical, progressive approach to provision of analgesic agents when managing 
many types of clinical pain.  
 
Figure 7. 
Severe case of laminitis. These cases can be extremely challenging to manage, often presenting with 
complex pain that is refractory to conventional analgesic protocols. Adjunctive approaches are as 
important as pharmacological therapy, with hoof wall resection and provision of adequate 
mechanical support illustrated here. 
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Epidural injection (here shown being performed at the sacro-coccygeal/first inter-coccygeal space) is a 
useful technique for achieving more targeted drug delivery. It is important to observe good hygiene and 
where possible to use preservative free drugs.  
 
149x107mm (150 x 150 DPI)  
 
 
Page 60 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Epidural catheter placed at the sacro-coccygeal/first inter-coccygeal space. Note the bacterial filter and 
sterile dressing to maintain cleanliness. With appropriate care, these can be maintained for several days for 
extended pain management without the requirement for repeated needle puncture.  
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Commercially available epidural catheter kits. Several makes are available and contain all the necessary 
components.    
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Commercially available wound diffusion catheters. These are available with different diffusion lengths so can 
be chosen to suit the extent of the surgical field. Home-made ones can be constructed from long 
intravenous cannulae or dog urinary catheters.  
 
159x119mm (150 x 150 DPI)  
 
 
Page 63 of 66
https://mc.manuscriptcentral.com/inpract
In Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Commercial wound diffusion catheter in-situ following spinous process resection. The catheter is placed 
during wound closure and exited through a stab incision distant from the surgical site. Note the bacterial 
filter to preserve sterility of injected local anaesthetic agent.  
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World Health Organisation ‘Pain Ladder’. Originally designed for guidance in managing cancer pain in people, 
it describes a logical, progressive approach to provision of analgesic agents when managing many types of 
clinical pain.  
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Severe case of laminitis. These cases can be extremely challenging to manage, often presenting with 
complex pain that is refractory to conventional analgesic protocols. Adjunctive approaches are as important 
as pharmacological therapy, with hoof wall resection and provision of adequate mechanical support 
illustrated here.  
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